|
|
|
| Clinical research of self-made Yiqi Huoxue Decection adjuvant therapy in the treatment of heart failure after acute myocardial infarction |
| XU Mujuan WANG Ling HAN Yue |
| Department of Critical Care Medicine, Shenzhen Traditional Chinese Medicine Hospital, Guangdong Province, Shenzhen 518033, China |
|
|
|
Abstract Objective To investigate clinical efficacy of self-made Yiqi Huoxue Decection adjuvant therapy in the treatment of heart failure after acute myocardial infarction (AMI). Methods Eighty patients with heart failure after AMI admitted to Shenzhen Traditional Chinese Medicine Hospital from June 2015 to February 2019 were divided into control group (40 cases) and study group (40 cases) according to random number table method. The patients in control group were treated with conventional treatment. The patients in study group were treated with self-made Yiqi Huoxue Decoction on the basis of control group. The patients in two groups were treated for 2 weeks continuously. The left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), central venous pressure (CVP), heart rate (HR), serum levels of high-sensitivity C-reactive protein (hs-CRP), tumor necrosis factor-α (TNF-α), interleukin-10 (IL-10), endothelin (ET), nitric oxide (NO) were measured and compared between two groups before and after treatment. The adverse reactions of two groups during the treatment were observed. Results After treatment, LVEF was higher than that before treatment, LVEDD was less than that before treatment, CVP was lower than that before treatment, HR was slower than that before treatment in two groups; after treatment, LVEF, LVEDD, CVP and HR in study group were significantly improved compared with those in control group, the differences were highly statistically significant (P < 0.01). After treatment, the levels of serum hs-CRP and TNF-α were lower than those before treatment, the level of IL-10 was higher than that before treatment in two groups; after treatment, the levels of serum hs-CRP, TNF-α and IL-10 in study group were significantly improved compared with those in control group, the differences were highly statistically significant (P < 0.01). After treatment, the level of serum ET was lower than that before treatment, the level of serum NO was higher than that before treatment in two groups; after treatment, the levels of ET and NO in study group were significantly improved compared with those in control group, the differences were highly statistically significant (P < 0.01). During treatment, there was no significant difference in incidence of adverse reactions between two groups (P > 0.05). Conclusion Clinical effect of self-made Yiqi Huoxue Decection adjuvant therapy in the treatment of heart failure after AMI is significant, which can significantly improve the cardiac function and inflammatory response, adjust the endothelial function and has good safety.
|
|
|
|
|
|
[1] 李兵.急性心肌梗死患者心血管内科的临床治疗效果分析[J].中国实用医药，2019，14（8）：85-86.
[2] 汪云春.浅析青年急性心肌梗死患者的临床特点及病因[J].世界最新医学信息文摘，2019，19（22）：47-48.
[3] 范文娟.急性心肌梗死后心力衰竭患者临床特征及预后分析[J].实用临床护理学电子杂志，2018，3（19）：20-22.
[4] 杨清勇，郭延松.心肌梗死后心力衰竭防治进展[J].福建医药杂志，2017，39（S1）：50-55.
[5] 邢冬梅，李彬，朱明军，等.中医药预防急性心肌梗死后心力衰竭的新思路[J].中华中医药杂志，2017，32（1）：196-198.
[6] 中华医学会心血管病学分会.急性ST段抬高型心肌梗死诊断和治疗指南[J].中华心血管病杂志，2015，43（5）：380-393.
[7] 葛均波，徐永健.内科学[M].8版.北京：人民卫生出版社，2013：166-169.
[8] 中国中西医结合学会心血管学会.冠心病中医辨证标准[J].中西医结合杂志，1991，11（5）：257.
[9] 高莎，张培影.心肌梗死后心力衰竭发生机制研究进展[J].中西医结合心脑血管病杂志，2018，16（11）：1520-1522.
[10] 宋丽萍，郭云飞，杨静文，等.急性心肌梗死后心力衰竭患者临床特征及预后分析[J].北京医学，2016，38（2）：114-117.
[11] 任保红.硝普钠、参麦注射液及米力农在治疗急性心肌梗死后心力衰竭的疗效观察[J].实用临床医药杂志，2017，21（15）：64-67.
[12] 李琳，王燕，苏林，等.冠心病及心肌梗死后心力衰竭病人血管内皮功能障碍与中医证型的相关性研究[J].中西医结合心脑血管病杂志，2016，14（14）：1569-1572.
[13] 黄平东，罗懿明，刘煜德，等.益气温阳活血利水药对心肌梗死后心力衰竭大鼠心功能和脑钠肽的影响[J].中西医结合心脑血管病杂志，2008，6（5）：538-539.
[14] 韩树山，吴爱明，张冬梅，等.益气活血方对心肌梗死后心力衰竭大鼠心功能的影响及其细胞凋亡机制[J].环球中医药，2013，6（7）：488-492.
[15] 景雅婷，王凤荣，刘月.温阳益心法联合西药治疗充血性心衰的临床疗效[J].河北医学，2019，25（8）：1351-1356.
[16] 周袁申，孔勇杰，魏丹丹，等.新通冠颗粒（芪麦通冠协定方）对急性心肌梗死后心力衰竭患者心功能影响的随机双盲对照研究[J].中国中西医结合杂志，2019，39（2）：151-156.
[17] 王东杰.急性心肌梗死患者IL-6、TNF-α、INF-γ、VEGF、Fg、hs-CRP水平变化及其与介入治疗关系的研究[J].国际检验医学杂志，2019，40（6）：750-753.
[18] 杨勇，谢文超.瑞舒伐他汀治疗急性心肌梗死后心力衰竭的疗效及对内皮功能、炎症因子的影响[J].中西医结合心脑血管病杂志，2018，16（13）：1861-1864.
[19] 方如民.重组人脑利钠肽治疗急性心肌梗死后心力衰竭临床疗效及对内皮功能和炎症因子的影响[J].山西医药杂志，2017，46（4）：378-380.
[20] 龙骁，陈然，程春，等.AMI后心力衰竭应用不同剂量培哚普利的疗效及对NT-proBNP及心肌能量消耗的影响[J].中国临床研究，2017，30（6）：740-743.
[21] 杜文涛.大鼠急性心肌梗死后血清脑钠肽、内皮素-1和一氧化氮的变化及卡托普利对其影响的研究[D].石家庄：河北医科大学，2008.
[22] 付蓉.参附注射液对心力衰竭大鼠炎症因子的影响[J].中药新药与临床药理，2012，23（1）：36-37. |
|
|
|
